Clinical efficacy and safety of Chiglitazar Sodium combined with Insulin Aspart 30 Injection in the treatment of patients with diabetes mellitus type 2
Objective To investigate the clinical efficacy and safety of Chiglitazar Sodium,a new panagonist of peroxisome proliferator-activated receptors(PPARs),in the treatment of diabetes mellitus type 2.Methods A total of 68 patients with diabetes mellitus type 2 admitted to the Weihai Branch of 970th Hospital of PLA Joint Logistics Support Force from January to June 2022 were selected as the study objects,and they were divided into observation group(n=34)and control group(n=34)according to random number table method.The control group was treated with Insulin Aspart 30 Injection,and the observation group was treated with Chiglitazar Sodium on the basis of the control group.The differences of homeostatic mod-el assessment of insulin resistance(HOMA-IR),homeostasis model assessment of β-cell function(HOMA-β),body mass index(BMI),blood glucose([glycosylated hemoglobin,HbA1c],[fasting plasma glucose,FPG],[2 h postprandial plasma glu-cose,2 h PG]),PPARs levels and adverse reactions were compared between the two groups before and after treatment.Re-sults The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P＜0.05).HOMA-IR,HbA1c,FPG and 2 h PG in observation group were lower than those in control group,the differences were statistically significant(P＜0.05).The levels of HOMA-β,PPARα,PPARβ and PPARγ in observation group were higher than those in control group,the differences were statistically significant(P＜0.05).There was no signifi-cant difference in BMI and adverse reactions between the two groups(P＞0.05).Conclusion Chiglitazar Sodium can effec-tively improve islet function and insulin resistance in dia-betes patients type 2,increase PPARs level,improve blood glucose control,improve treatment effect,and reduce ad-verse reactions.
Chiglitazar SodiumIslet functionInsulin resistanceDiabetes mellitus type 2Adverse reaction
万方数据
维普
